Statement: The only adverse event observed in Patients from both the secondary trial and the primary trial, was Endocervical cancer.
Primary_evidence: Adverse Events 1:   Total: 14/69 (20.29%)   Febrile neutropenia  0/69 (0.00%)   Anaemia  0/69 (0.00%)   Atrial fibrillation  1/69 (1.45%)   Cardiopulmonary failure  0/69 (0.00%)   Supraventricular extrasystoles  1/69 (1.45%)   Abdominal pain  1/69 (1.45%)   Intestinal obstruction  0/69 (0.00%)   Vomiting  1/69 (1.45%)   Chills  1/69 (1.45%)   Oedema peripheral  0/69 (0.00%)   Pyrexia  1/69 (1.45%) Adverse Events 2:   Total: 17/66 (25.76%)   Febrile neutropenia  6/66 (9.09%)   Anaemia  1/66 (1.52%)   Atrial fibrillation  1/66 (1.52%)   Cardiopulmonary failure  1/66 (1.52%)   Supraventricular extrasystoles  0/66 (0.00%)   Abdominal pain  0/66 (0.00%)   Intestinal obstruction  1/66 (1.52%)   Vomiting  0/66 (0.00%)   Chills  0/66 (0.00%)   Oedema peripheral  1/66 (1.52%)   Pyrexia  0/66 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 0/244 (0.00%)   Pregnancy *0/244 (0.00%)   Endocervical cancer *0/244 (0.00%)   Nosocomial pneumonia *0/244 (0.00%)   Venous thrombosis *0/244 (0.00%) Adverse Events 2:   Total: 5/255 (1.96%)   Pregnancy *1/255 (0.39%)   Endocervical cancer *1/255 (0.39%)   Nosocomial pneumonia *2/255 (0.78%)   Venous thrombosis *1/255 (0.39%)